Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Tuberous Sclerosis 1Recurrence 1Polycystic Ovary Syndrome 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Focal Cortical Dysplasia 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumours 1Advanced Solid Tumors 1

Interventions

pembrolizumab 29Capecitabine 24Bevacizumab 23Cyclophosphamide 22Gemcitabine 21Paclitaxel 20Nivolumab 19Fluorouracil 19Docetaxel 18aldesleukin 17Leucovorin 17Irinotecan 17Oxaliplatin 15Interleukin-2 14Radiosurgery 13Cisplatin 13Cetuximab 13fludarabine 12Carboplatin 12Albumin-Bound Paclitaxel 11fludarabine phosphate 10Ipilimumab 10Drug Therapy 10Doxorubicin 10Sunitinib 9Radiotherapy 9Everolimus 9130-nm albumin-bound paclitaxel 9Trastuzumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasm Metastasis × Itraconazole × Clear all
NCT01450683 2017-04-11

Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

Stanford University

Phase 2 Terminated
4 enrolled 4 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡